E. Imamura

发表

Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.

M. Sakurai, Y. Matsumura, M. Imanishi, 2008, Journal of medicinal chemistry.

ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor for the Treatment of Allergic Diseases

Hiroshi Suzuki, Y. Saita, E. Imamura, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Anti‐IL‐23 receptor monoclonal antibody prevents CD4+ T cell‐mediated colitis in association with decreased systemic Th1 and Th17 responses

E. Imamura, S. Kubo, T. Morokata, 2018, European journal of pharmacology.

AS2762900‐00, a potent anti‐human IL‐23 receptor monoclonal antibody, prevents epidermal hyperplasia in a psoriatic human skin xenograft model

E. Imamura, S. Kubo, Y. Okada, 2019, European journal of pharmacology.

Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.

H. Kayakiri, Y. Tomishima, H. Hamashima, 2005, Bioorganic & medicinal chemistry letters.

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors

Yoshiya Tanaka, S. Nakayamada, E. Imamura, 2019, Rheumatology.

Generation and characterization of a potent fully human monoclonal antibody against the interleukin‐23 receptor

M. Ohori, E. Imamura, S. Kubo, 2018, European journal of pharmacology.

Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.

Nobuhiro Yamamoto, Minoru Sakurai, Yutaka Nakajima, 2008, Bioorganic & medicinal chemistry letters.

Anti-Inflammatory Profile of AS2444697, A Novel Interleukin-1 Receptor-Associated Kinase-4 Inhibitor

T. Kontani, E. Imamura, Y. Shimizu, 2011 .

Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.

M. Sakurai, Y. Matsumura, M. Imanishi, 2009, Journal of medicinal chemistry.

Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.

M. Sakurai, Y. Matsumura, M. Imanishi, 2008, Journal of medicinal chemistry.

Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.

M. Sakurai, Y. Matsumura, M. Imanishi, 2008, Journal of medicinal chemistry.

Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction.

T. Kontani, E. Imamura, T. Ishikawa, 2023, Bioorganic & medicinal chemistry.